| Nicotinic acid, alone and in combinations, for reduction of cardiovascular risk. | |
| | |
MedLine Citation:
|
PMID: 18375243 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
The current guidelines for the treatment of high risk lipid disorders do not specify a therapeutic target level of high-density lipoprotein (HDL) cholesterol for cardiovascular disease prevention in high-risk populations. However, as described in this report, there is a substantial body of evidence from basic science and epidemiologic studies and from clinical trials providing the strong, consistent message that raising HDL cholesterol by therapeutic means will effectively reduce cardiovascular risk independently of reductions in low-density lipoprotein (LDL) cholesterol. Therapeutic HDL cholesterol raising, most effectively achieved by nicotinic acid (niacin), appears to be at least as effective as comparable percentages of LDL cholesterol lowering for the reduction of atherosclerosis progression or clinical cardiovascular events, over a broad range of risk levels. The widespread adoption of this strategy awaits the results of large, ongoing controlled clinical trials of HDL cholesterol raising. |
| | |
Authors:
|
B Greg Brown; Xue-Qiao Zhao |
Related Documents
:
|
3866583 - Lipid levels in high density lipoprotein subfractions in smokers with peripheral vascul... 11520483 - What are the priorities for managing cholesterol effectively? 2094163 - Effects of dietary lipidic charge in the concentration of bovine plasmatic lipids and l... |
Publication Detail:
|
Type: Journal Article; Review |
Journal Detail:
|
Title: The American journal of cardiology Volume: 101 ISSN: 0002-9149 ISO Abbreviation: Am. J. Cardiol. Publication Date: 2008 Apr |
Date Detail:
|
Created Date: 2008-03-31 Completed Date: 2008-07-02 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 0207277 Medline TA: Am J Cardiol Country: United States |
Other Details:
|
Languages: eng Pagination: 58B-62B Citation Subset: AIM; IM |
Affiliation:
|
Division of Cardiology, Department of Medicine, University of Washington School of Medicine, Seattle, Washington 98195-8019, USA. bgbrown@u.washington.edu |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Anticholesteremic Agents
/
therapeutic use* Cardiovascular Diseases / etiology, prevention & control* Cholesterol, HDL / drug effects Cholesterol, LDL / drug effects Clofibric Acid / therapeutic use Drug Therapy, Combination Dyslipidemias / complications, drug therapy* Humans Hyperlipidemias / drug therapy Niacin / pharmacology, therapeutic use* Risk Factors Risk Reduction Behavior |
| Chemical | |
Reg. No./Substance:
|
0/Anticholesteremic Agents; 0/Cholesterol, HDL; 0/Cholesterol, LDL; 59-67-6/Niacin; 882-09-7/Clofibric Acid |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Comprehensive lipid management versus aggressive low-density lipoprotein lowering to reduce cardiova...
Next Document: The safety of niacin in the US Food and Drug Administration adverse event reporting database.